At a Glance

• AEHR fell 9.1% to $132.37 on Tuesday, with trading volume down 79% from its average.
• The stock carries a consensus "Buy" rating and an average price target of $136.67.
• Jefferies initiated coverage this week with a "Buy" rating and a $175 price target.
• Insiders sold 109,475 shares worth $13.8 million over the past 90 days.
• Institutional investors, including Vanguard and UBS, own roughly 69.7% of the company.

Shares of Aehr Test Systems (AEHR) dropped 9.1% on Tuesday, hitting $132.37 in midday trading after closing the previous session at $145.61.

Volume was notably thin. Only around 520,330 shares changed hands, a 79% decline from the average daily volume of 2,424,321.

The company behind the ticker occupies a niche of the semiconductor supply chain that has drawn growing investor interest alongside this year's AI-driven rally in chip-equipment names. Aehr, headquartered in Fremont, California, builds wafer-level test and burn-in systems for chip production — a business long anchored in silicon carbide power devices for electric vehicles that the company has said it is extending into gallium nitride and burn-in of AI processors.

The 12-month range reflects how quickly the stock has moved. AEHR traded as low as $16.38 over the past year and reached a high of $147.40 just recently. At current prices, the company carries a market capitalization of roughly $4.03 billion. Its P/E ratio stands at -519.12 — a negative multiple, indicating trailing twelve-month losses — and the stock has a beta of 3.10, reflecting a history of sharp swings.

Analyst Outlook Remains Positive

Despite the drop, Wall Street's view on AEHR is broadly constructive. The stock holds an average "Buy" rating from analysts, with a consensus price target of $136.67, slightly above where shares changed hands Tuesday.

Jefferies initiated coverage this week with a "Buy" rating and a $175 price target, one of the more bullish calls on the street at the moment.

Freedom Capital and Zacks Research both upgraded AEHR to "Strong Buy" in July. Wall Street Zen moved from "Sell" to "Hold" around the same time. Craig Hallum reaffirmed its "Buy" rating in July with a $125 price target. Weiss Ratings moved in the opposite direction, downgrading from "Sell (D)" to "Sell (E+)" at the end of July.

Of the seven analysts tracked, two assign "Strong Buy" ratings, four assign "Buy" ratings, and one has a "Sell."

Insider Selling Draws Attention

Insider activity is hard to ignore. Over the past 90 days, insiders sold a combined 109,475 shares worth $13.8 million.

COO Adil Engineer sold 15,000 shares on August 12 at an average price of $131.02, a transaction totaling $1.97 million that cut his position by 24.2%. EVP Alberto Salamone sold 9,672 shares on August 13 at $127.72, bringing in roughly $1.24 million and reducing his stake by 18.7%. Director Howard T. Slayen sold 20,000 shares on August 4 at $108.30, a transaction worth $2.17 million that trimmed his position by around 12%.

Insiders now own 6.8% of the company in total. Research on insider transactions has generally found sales to be a weaker signal than purchases, since executives can have many reasons to sell — diversification, tax obligations, personal expenses — and fewer reasons to buy.

On the institutional side, Royal Bank of Canada increased its stake by 15.3% in the first quarter, adding 7,968 shares to bring its total to 59,939. Vanguard lifted its position by 2.2%, while UBS boosted its holdings by 55.7%. Institutional investors collectively own 69.69% of the company.

The 50-day moving average stands at $93.83 and the 200-day moving average at $72.59, both well below the current price. Both ownership pictures will keep refreshing on a set schedule: Form 4s are filed within two business days of insider trades, while quarterly 13F filings update the institutional breakdown.

Source: CoinCentral